BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2026 6:39:38 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-06-29 08:31 |
|
Peer-Review Started |
|
2026-06-29 08:31 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-07-15 07:18 |
|
Revised |
|
2026-08-07 08:15 |
|
Publication Fee Transferred |
|
2026-09-08 13:45 |
|
Second Decision by Editor |
|
2026-09-21 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-09-30 07:45 |
|
Articles in Press |
|
2026-09-30 07:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-10-20 09:24 |
|
Publish the Manuscript Online |
|
2026-10-26 06:39 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Review |
| Article Title |
Stem cell therapy for endocrine and metabolic disorders
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Dong-Qing Lv, Ming Xu, Sen-Jie Li, Shu-Qing Jin, Qin-Hao Liu, Jing Zhou, Jia-Ning Lv, Yun-Feng Liu and Yi Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Shanxi Province Basic Research Program |
202303021212321 |
| Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project |
BYJL024 |
| Shanxi Provincial Health Commission 2026 Strengthening Basic Disciplines Plan for Science and Technology Advancing Medical Innovation Program |
2026QJGC010 |
|
| Corresponding Author |
Yun-Feng Liu, MD, PhD, Professor, Department of Endocrinology, First Hospital of Shanxi Medical University, No. 85 Jiefang South Road, Taiyuan 030000, Shanxi Province, China. nectarliu@163.com |
| Key Words |
Stem cell therapy; Diabetes; Hypothyroidism; Hypopituitarism; Primary adrenal insufficiency; Osteoporosis |
| Core Tip |
This review provides the first systematic comparison of pluripotent and mesenchymal stem cell strategies across major endocrine and metabolic disorders, diabetes, hypothyroidism, hypopituitarism, adrenal insufficiency, and osteoporosis. We establish a clear functional framework: Pluripotent stem cells-mediated cell replacement is applicable to diseases characterized by irreversible cell loss, whereas mesenchymal stem cell-mediated anti-inflammatory and immunomodulatory actions are applicable to inflammation- or immune-driven conditions. We also identify translational barriers and propose actionable solutions, offering a roadmap from proof-of-concept toward clinical practice. |
| Publish Date |
2026-10-26 06:39 |
| Citation |
Lv DQ, Xu M, Li SJ, Jin SQ, Liu QH, Zhou J, Lv JN, Liu YF, Zhang Y. Stem cell therapy for endocrine and metabolic disorders. World J Stem Cells 2026; 18(10): 124937
|
| URL |
https://www.wjgnet.com/1948-0210/full/v18/i10/124937.htm |
| DOI |
https://doi.org/10.4252/wjsc.124937 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
